Objective: To assess the efficacy and safety profile of docetaxel, as a single agent, in the treatment of elderly patients with advanced breast cancer. Methods: Twenty-eight patients, with a ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

CD47 expression may serve as a positive prognostic biomarker in metastatic NSCLC, correlating with better outcomes in patients treated with magrolimab plus docetaxel. Patients with metastatic ...

Docetaxel is the current standard of care for NSCLC patients without targetable alterations who progress on PD-(L)1 inhibitor-based therapy, however, it is associated with modest clinical benefit ...

The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic ...

When should Docetaxel not be taken ... Monitor liver blood function and blood counts regularly. Treatment with corticosteroids before starting this medication is recommended.

These agents have been successfully introduced into the treatment paradigms of a variety ... 2–14 of a 3-week cycle in combination with docetaxel (administered on day 1 in both cases).

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

Question has been topic of heated discussion after Congress leader Navjot Sidhu claimed dietary changes helped his wife beat ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...